- Home
- FBRT vs PHAT Comparison
FBRT vs PHAT Comparison
Compare FBRT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FBRT | PHAT |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.9M | 590.6M |
| IPO Year | 2012 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FBRT | PHAT |
|---|---|---|
| Price | $6.18 | $7.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $11.67 | ★ $20.45 |
| AVG Volume (30 Days) | ★ 2.1M | 1.2M |
| Earning Date | 10-28-2026 | 10-29-2026 |
| Dividend Yield | ★ 13.07% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $270,071,000.00 | $175,110,000.00 |
| Revenue This Year | N/A | $80.58 |
| Revenue Next Year | $9.88 | $56.62 |
| P/E Ratio | $32.21 | ★ N/A |
| Revenue Growth | 28.33 | ★ 216.93 |
| 52 Week Low | $6.03 | $6.52 |
| 52 Week High | $10.88 | $18.31 |
Technical Indicators
Market Signals| Indicator | FBRT | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 24.64 | 39.88 |
| Support Level | N/A | $6.91 |
| Resistance Level | $9.32 | $9.74 |
| Average True Range (ATR) | 0.24 | 0.31 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 6.92 | 58.16 |
Price Performance
Historical ComparisonAbout FBRT Franklin BSP Realty Trust Inc.
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. The Company's operations are organized into two business units: (i) Commercial Real Estate Financing, and (ii) Agency Business. Its four reporting segments are as follows: The real estate debt business, The Agency Business, The commercial real estate conduit business, and The real estate owned business.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.